$1.38
-0.03 (-2.13%)
Open$1.40
Previous Close$1.41
Day High$1.41
Day Low$1.36
52W High$3.19
52W Low$0.87
Volume—
Avg Volume306.1K
Market Cap81.51M
P/E Ratio—
EPS$-0.68
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,493.5% upside
Current
$1.38
$1.38
Target
$21.99
$21.99
$18.66
$21.99 avg
$31.61
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 31.19M | 31.61M | 26.89M |
| Net Income | 2.24M | 2.16M | 1.99M |
| Profit Margin | 7.2% | 6.8% | 7.4% |
| EBITDA | 3.54M | 3.42M | 2.98M |
| Free Cash Flow | 1.72M | 2.00M | 2.13M |
| Rev Growth | -3.9% | +21.8% | -6.2% |
| Debt/Equity | 0.32 | 0.27 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |